By Fineline Cube 
METiS Therapeutics (HKG: 7666) holding company METiS Life Sciences and JOINN Biologics officially signed a joint venture agreement to establish JOINMETiS Biopharma, aiming to join forces in creating an innovative R&D and industrial manufacturing platform for mRNA therapeutics. Under the agreement, METiS contributes upstream design and delivery capabilities through its NanoForge platform, while JOINN Biologics provides downstream manufacturing and quality control across the full mRNA process chain — combining two complementary infrastructure leaders into a single end‑to‑end mRNA engine.
Joint Venture Snapshot
| Item | Detail |
|---|---|
| Parties | METiS Life Sciences (holding company of METiS Therapeutics, HKG: 7666); JOINN Biologics |
| Entity | JOINMETiS Biopharma (joint venture) |
| Signing Date | 4 September 2026 |
| Objective | Innovative R&D and industrial manufacturing platform for mRNA therapeutics |
| METiS Contribution | Upstream design and targeted delivery (NanoForge platform) |
| JOINN Contribution | Downstream manufacturing, quality control, and regulatory filing |
| Ownership & Financial Terms | Not disclosed |
Upstream Capabilities – METiS NanoForge Platform
- Platform: NanoForge, METiS’s proprietary nanoparticle design and delivery platform.
- Organ Targeting: Has achieved targeted delivery to 8 key human organs and tissues — extending mRNA reach beyond the liver, the historic default destination for lipid nanoparticle payloads.
- Commercial Traction: Serves more than 30 global pharmaceutical and biotechnology partners.
- Intellectual Property: 224 patent applications filed and 52 patents granted as of April 2026.
Downstream Capabilities – JOINN Biologics Manufacturing Chain
- Full‑Chain Coverage: The JOINN platform spans plasmid preparation, in vitro transcription and capping modification, purification, and LNP encapsulation, through to pilot‑scale formulation filling, release testing, and regulatory filing.
- Facility Readiness: Capacity for pilot scale, IND‑enabling studies, and small‑scale commercial production is already in place — shortening the path from design to clinic.
- Personalized‑Medicine Design: To address the small‑batch, high‑frequency nature of personalized mRNA therapies, the platform will feature flexible production scheduling and digital management systems adapted to dynamic production.
Market Impact & Outlook
- End‑to‑End Integration: By pairing NanoForge’s multi‑organ delivery design with JOINN’s plasmid‑to‑filing manufacturing chain, JOINMETiS Biopharma addresses the two critical bottlenecks of mRNA development — extrahepatic targeting and GMP‑grade process scale‑up — under one roof.
- Next‑Generation mRNA Positioning: The JV’s emphasis on personalized mRNA therapies and flexible small‑batch manufacturing aligns with the field’s shift beyond pandemic vaccines toward individualized cancer vaccines and rare‑disease medicines.
- Partner Network Leverage: METiS’s 30+ global partners provide a ready commercial funnel for the JV’s services, while JOINN’s established biologics manufacturing footprint anchors industrial execution.
- Strategic Context: The collaboration deepens the alliance between METiS Therapeutics (HKG: 7666) and the JOINN ecosystem, though JV ownership, governance, and investment amounts were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the establishment and operations of JOINMETiS Biopharma, platform development, and commercial expectations for the joint venture. Actual results may differ materially due to risks including JV execution, regulatory approvals, manufacturing scale‑up, technology performance, and competitive dynamics in the mRNA therapeutics market.-Fineline Info & Tech